WCG
TAK icon

Weaver Consulting Group’s Takeda Pharmaceutical TAK Stock Holding History

Weaver Consulting Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-300
Closed -$5K – 809
2020
Q3 		$5K Hold
300
– – ﹤0.01% 699
2020
Q2 		$5K Hold
300
– – ﹤0.01% 670
2020
Q1 		$5K Hold
300
– – ﹤0.01% 572
2019
Q4 		$5K Hold
300
– – ﹤0.01% 624
2019
Q3 		$5K Buy
300
+145
+94% +$2.51K ﹤0.01% 609
2019
Q2 		$3K Hold
155
– – ﹤0.01% 675
2019
Q1 		$3K Buy
+155
New +$3.12K ﹤0.01% 1254

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM

Weaver Consulting Group's TAK Position: Q4 2020 in Review

Weaver Consulting Group sold out of Takeda Pharmaceutical (TAK) in Q4 2020, closing a stake of 300 shares — an estimated $5K sold.

Weaver Consulting Group first reported a position in TAK in Q1 2019 and held it in 7 quarters. The position peaked at $5K in Q3 2020. 312 funds tracked by Wall St. Rank hold TAK as of Q4 2020.

  • Weaver Consulting Group reported no remaining Takeda Pharmaceutical position as of Q4 2020 after selling out during the quarter.
  • Weaver Consulting Group sold 300 Takeda Pharmaceutical shares in Q4 2020, an estimated $5K.
  • Weaver Consulting Group first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 7 quarters.
  • Weaver Consulting Group's Takeda Pharmaceutical position peaked at $5K in Q3 2020.
  • 312 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2020.

Based on Weaver Consulting Group's 13F filing for Q4 2020, filed 29 Jan 2021.